AU2015342801A1 - Ornithine aminotransferase inhibition with GABA Analogues for treatment of hepatocellular carcinoma - Google Patents

Ornithine aminotransferase inhibition with GABA Analogues for treatment of hepatocellular carcinoma Download PDF

Info

Publication number
AU2015342801A1
AU2015342801A1 AU2015342801A AU2015342801A AU2015342801A1 AU 2015342801 A1 AU2015342801 A1 AU 2015342801A1 AU 2015342801 A AU2015342801 A AU 2015342801A AU 2015342801 A AU2015342801 A AU 2015342801A AU 2015342801 A1 AU2015342801 A1 AU 2015342801A1
Authority
AU
Australia
Prior art keywords
compound
subject
day
cpp
oat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2015342801A
Other languages
English (en)
Inventor
Yaron Ilan
Richard B. Silverman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hadasit Medical Research Services and Development Co
Northwestern University
Original Assignee
Hadasit Medical Research Services and Development Co
Northwestern University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hadasit Medical Research Services and Development Co, Northwestern University filed Critical Hadasit Medical Research Services and Development Co
Publication of AU2015342801A1 publication Critical patent/AU2015342801A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
AU2015342801A 2014-11-07 2015-11-09 Ornithine aminotransferase inhibition with GABA Analogues for treatment of hepatocellular carcinoma Abandoned AU2015342801A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462076980P 2014-11-07 2014-11-07
US62/076,980 2014-11-07
PCT/US2015/059738 WO2016073983A2 (en) 2014-11-07 2015-11-09 Ornithine aminotransferase inhibition with gaba analogues for treatment of hepatocellular carcinoma

Publications (1)

Publication Number Publication Date
AU2015342801A1 true AU2015342801A1 (en) 2017-05-18

Family

ID=55910047

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015342801A Abandoned AU2015342801A1 (en) 2014-11-07 2015-11-09 Ornithine aminotransferase inhibition with GABA Analogues for treatment of hepatocellular carcinoma

Country Status (9)

Country Link
US (1) US9603820B2 (OSRAM)
EP (1) EP3215144B1 (OSRAM)
JP (1) JP6867949B2 (OSRAM)
AU (1) AU2015342801A1 (OSRAM)
CA (1) CA2966642C (OSRAM)
ES (1) ES2882126T3 (OSRAM)
IL (1) IL252042B (OSRAM)
MX (1) MX2017006022A (OSRAM)
WO (1) WO2016073983A2 (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210009306A (ko) * 2018-03-29 2021-01-26 오비드 테라퓨틱스 인크. 눈 장애의 치료에서 (1s, 3s)-3-아미노-4-(디플루오로메틸리덴)시클로펜탄-1-카르복실산 및 (s)-3-아미노-4-(디플루오로메틸에닐)시클로펜트-1-엔-1-카르복실산의 용도
US10822301B2 (en) 2018-04-12 2020-11-03 Northwestern University 3-carbon substituted 4-aminocyclopent-1-ene-1-carboxylic acid compounds as inhibitors of gamma-aminobutyric acid (GABA) aminotransferase
IL278932B2 (en) 2018-05-25 2024-03-01 Univ Northwestern PROCESS FOR THE SYNTHESIS OF (S)-3-AMINO-4-(DIFLUOROMETHYLENYL)CYCLOPENT-l-ENE-l-CARBOXYLIC ACID
IL304270B2 (en) 2018-06-07 2024-10-01 Ovid Therapeutics Inc Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders
WO2020176511A1 (en) * 2019-02-25 2020-09-03 Northwestern University Analogs of 3-amino-4-(propan-2-ylidene) cyclopentane-1-carboxylic acid and uses thereof for treating diseases and disorders associated with ornithine aminotransferase activity
WO2020206234A1 (en) * 2019-04-03 2020-10-08 Northwestern University 2-difluoro substituted 4-aminocyclopentanecarboxylic acids as inhibitors of gamma-aminobutyric acid aminotransferase and human ornithine aminotransferase
US11993569B2 (en) 2020-01-23 2024-05-28 Northwestern University 3-amino-4-halocyclopentene carboxylic acids as inactivators of aminotransferases
CN117321025A (zh) * 2021-03-03 2023-12-29 西北大学 作为人鸟氨酸氨基转移酶的选择性灭活剂的(s)-3-氨基-4,4-二卤代环戊-1-烯甲酸
EP4326743A1 (en) * 2021-04-20 2024-02-28 BicycleTX Limited Bicyclic peptide ligands specific for p-selectin
EP4387675A1 (en) * 2021-08-19 2024-06-26 N1 Life, Inc. Taxol conjugate compounds, pharmaceutical compositions comprising the same, and methods for their use
WO2024196851A1 (en) * 2023-03-17 2024-09-26 Northwestern University Bicyclic compounds as inactivators of oat and gaba-at

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794413B1 (en) 2002-07-19 2004-09-21 Northwestern University Compounds and related methods for inhibition of γ-aminobutyric acid aminotransferase
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
IL177609A (en) 2006-08-21 2015-11-30 Yaron Ilan Use of gobacoline or its analogue to produce a drug to treat liver carcinoma

Also Published As

Publication number Publication date
EP3215144A4 (en) 2018-06-20
ES2882126T3 (es) 2021-12-01
EP3215144A2 (en) 2017-09-13
US9603820B2 (en) 2017-03-28
JP6867949B2 (ja) 2021-05-12
IL252042A0 (en) 2017-06-29
IL252042B (en) 2020-05-31
US20160128958A1 (en) 2016-05-12
WO2016073983A3 (en) 2016-08-11
MX2017006022A (es) 2017-11-17
CA2966642C (en) 2023-03-28
WO2016073983A2 (en) 2016-05-12
CA2966642A1 (en) 2016-05-12
EP3215144B1 (en) 2021-04-28
JP2017533964A (ja) 2017-11-16

Similar Documents

Publication Publication Date Title
EP3215144B1 (en) Ornithine aminotransferase inhibition with gaba analogues for treatment of hepatocellular carcinoma
AU2017284160B2 (en) FXR (NR1H4) modulating compounds
US20200323866A1 (en) Ezh2 inhibitors for treating lymphoma
US12258336B2 (en) Preparation of seimicarbazide-sensitive amine oxidase inhibitor and use thereof
US12233128B2 (en) Degraders that target ALK and therapeutic uses thereof
US10961189B2 (en) Spiro-lactam NMDA receptor modulators and uses thereof
Fan et al. Design, synthesis, and biological evaluation of a novel indoleamine 2, 3-dioxigenase 1 (IDO1) and thioredoxin reductase (TrxR) dual inhibitor
KR20180041234A (ko) 레보도파로 유발된 이상운동증 치료용 뇌 침투성 크로몬 옥심 유도체
CN112638866A (zh) 索拉非尼衍生物的共晶体及其制备方法
CN109942630B (zh) 基于柳胺酚和紫檀芪的天然活性分子偶联化合物及其用途
US11426371B2 (en) Compositions and methods for treating cancer
US12486246B2 (en) Replication protein A (RPA)-DNA interaction inhibitors
WO2024196851A1 (en) Bicyclic compounds as inactivators of oat and gaba-at
WO2025250811A1 (en) Thymidine analogs and methods for their use in the treatments of cancer and other diseases
WO2023031683A1 (en) 2,4-dioxo-1,2,3,4-tetrahydropyrimidine derivatives and their use in the treatment of tumors
HK40097684A (en) Ezh2 inhibitors for treating lymphoma
WO2024196853A1 (en) Substituted cyclohexene and cyclohexane inhibitors of ornithine aminotransferase
AU2024278807A1 (en) Mitochondria specific transcription inhibitors
HK40050156B (en) Co-crystal of sorafenib derivatives and process for preparation thereof
HK40050156A (en) Co-crystal of sorafenib derivatives and process for preparation thereof

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application